Fractionated Stereotactic Radiosurgery for Large Brain Metastases
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/7/2018 |
| Start Date: | July 2013 |
| End Date: | December 2020 |
| Contact: | Karen D Holeva, BS |
| Email: | holevakd@upmc.edu |
| Phone: | 412-623-1275 |
PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES
This is a research trial that seeks to break up the total radiation dose into multiple
smaller radiation treatments, termed fractionated stereotactic radiosurgery (FSRS) which may
make the treatment feasible. Fractionated sterotatcic radiation, the risks of FSRS, and
possible costs will be described later in this document. This clinical trial is for people
who have had no prior whole brain radiation.
smaller radiation treatments, termed fractionated stereotactic radiosurgery (FSRS) which may
make the treatment feasible. Fractionated sterotatcic radiation, the risks of FSRS, and
possible costs will be described later in this document. This clinical trial is for people
who have had no prior whole brain radiation.
Inclusion Criteria:
- Male or female patients ≥ 18 years of age
- A life expectancy of at least 12 weeks with a Karnofsky performance status of at least
70 (Appendix II)
- The target lesion(s) can be accurately measured in at least one dimension according to
RECIST
- No prior radiotherapy to the brain
- Previous or concurrent systemic or targeted chemotherapy is allowed.
- Patients must have an extra-cranial primary tumor diagnosis
- Patients will have no more than 3 distinct lesions within the brain.
- At least 1 lesion must be a minimum of 3cm in greatest dimension, no larger than 5cm
which will be treatable by fractionated stereotactic radiosurgery
- The additional lesions will each be treated with single fraction stereotactic
radiosurgery
- Patient may be on steroids or anti-epileptics
- Must be aware of the neoplastic nature of his/her disease and willingly provide
written, informed consent after being informed of the procedure to be followed, the
experimental nature of the therapy, alternatives, potential benefits, side-effects,
risks and discomforts
- Patients do not need a histologically proven diagnosis of brain mets
Exclusion Criteria:
- Symptomatic patients in need of surgery to the "target" lesion
- Four or more newly-diagnosed lesions
- Prior surgical resection of targeted tumor
- Prior WBRT
- Primary brain tumor
- Pregnant or breast-feeding patients
- Primary tumor histology of lymphoma, leukemia, multiple myeloma or germ cell tumor
We found this trial at
1
site
Click here to add this to my saved trials
